Tres-Orix Forte Oral Solution Vitamin supplement/weight gain 250 ml for sale
Oral Solution 100ml
Composition Per 5ml of solution
Cyproheptadine orotate 1.5 mg
Carnitine chlorhydrate 150 mg
Lysine chlorhydrate 150 mg
Vitamin B1 10 mg
Vitamin B6 10 mg
Vitamin B12 100mg
Coenzyme B12 —
Excipients, s.q. (Containing 2.5mg of saccharine sodique and 75mg of ethanol)
Pharmaceutical forms and contents
Solution for oral use. Bottles of 100 ml.
Anorexia in children and adolescent, whether of and organic or emotional-psychological cause post infections anorexia. Deficiency anorexia. Retardation in growth. Anorexia of the infant, Habitual vomiting(excluding when of an organic origin). Emotional instability when accompanied by anorexic crises. Anorexia of the adult Constitutional thinness.
Hypersensivity to the components, Glaucoma, Predisposition to urine retention, Newborns.
Tres-orix Forte should not be administered simultaneously with other medicines which are Central Nervous System depressors.
Warnings on Excipients
Tres-Orix Forte Oral Solution:
It contains ethanol as excipient, which can be cause of risk in patients with hepatic disease, alcoholism, epilepsy and in pregnant women and children.
Dosage and administration
a) Capsules: One before each of main meals(3/day).
b) Oral solution: Two teaspoonfuls of 5 ml before breakfast, lunch, and dinner.
Infants: Two teaspoonfuls of 2.5 ml daily, distributed in two intakes.
Up to 7 to 12 years old: One teaspoonful of 5 ml before breakfast, lunch, and dinner, or one capsule before breakfast and one before dinner(2 days).
These doses are approximate, indicative doses, as it is known that responses to the preparations of this group are different according to individual idiosyncrasies of each patient. This appearance of drowsiness is a good sign for calculating the dosage and is even desirable it slightly appears in nervous children because their psychic condition improves simultaneously. However, drowsiness tends to disappear a few days after treatment is begun.
The effects of treatment are usually observed between 4 and 10 days after administration is initiated. Treatment can be administered for periods of one or two months with rest periods of 15 days to 1 month, without any undesirable side effect having been noticed nor any alteration of the humoral constants.
At therapeutic doses, there is no risk of intoxication. In the event of a massive accidental ingestion, the patient should be kept under strict observation and symptomatic measures should be taken.
In adults drowsiness can occur, for which reason cautions is recommended in driving or in performing tasks requiring alertness.
If you notice any side effects not mentioned in this leaflet, please inform your doctor or pharmacist.
Do not use this drug after the expiry date given on the package.
Neither all presentations nor all pharmaceutical forms are available in all markets
Under medical prescription
Keep out of the reach of children